Table 2

Efficacy outcomes by treatment group

Efficacy measuresNPX
N=40
No treatment
N=40
p Value for treatment group difference
Week 28, meanWeek 52, meanChange, mean (SD)%
Change
Week 28, meanWeek 52, meanChange, mean (SD)%
change
ASDAS0.91.50.6 (0.71)145.81.01.60.6 (0.63)95.50.84
BASDAI (10 cm VAS)0.71.20.6 (1.06)71.30.51.71.1 (1.37)214.50.11
BASMI (10 cm VAS)1.51.80.3 (0.47)30.21.61.70.3 (0.63)19.60.89
BASFI (10 cm VAS)0.61.00.5 (0.79)73.50.61.50.9 (1.41)144.10.30
CRP (mg/dl)0.370.690.29 (0.924)85.00.530.720.26 (0.707)34.30.99
ESR (mm/h)7.114.77.6 (11.63)209.89.413.65.1 (10.10)134.00.46
EQ-5D index score*0.850.73−0.12 (0.228)−13.90.840.74−0.12 (0.232)−12.00.95
  • *An increase in this score indicates improvement. For all other measures, a decrease in score indicates improvement.

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; EQ-5D, EuroQoL 5D Health Questionnaire; VAS, visual analogue scale.